Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing

Pharmacogenomics Journal

Volumn 16, Issue 1, 2016, Pages 60-70

  Tourancheau, A ^a,b   Margaillan, G ^a,b   Rouleau, M ^a,b   Gilbert, I ^a,b   Villeneuve, L ^a,b   Levesque E ^a,b   Droit, A ^b   Guillemette, C ^a,b,c  

^a University Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; TRANSCRIPTOME; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; EXON; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCUS; GENE STRUCTURE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOME; GLUCURONIDATION; HUMAN; HUMAN TISSUE; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA SEQUENCE; TRANSCRIPTOMICS; UGT1 GENE; UGT2 GENE; ANTIBODY SPECIFICITY; BREAST; BREAST TUMOR; ENDOMETRIUM; ENZYMOLOGY; FEMALE; GENETICS; INTESTINE; INTESTINE TUMOR; KIDNEY; KIDNEY TUMOR; LIVER; LIVER TUMOR; MALE; METABOLISM; PROCEDURES; PROSTATE; PROSTATE TUMOR; SEQUENCE ANALYSIS; UTERUS CANCER; XENOBIOTIC METABOLISM;

BREAST; BREAST NEOPLASMS; ENDOMETRIUM; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINAL NEOPLASMS; INTESTINES; KIDNEY; KIDNEY NEOPLASMS; LIVER; LIVER NEOPLASMS; MALE; METABOLIC DETOXICATION, PHASE II; ORGAN SPECIFICITY; PROSTATE; PROSTATIC NEOPLASMS; RNA, MESSENGER; SEQUENCE ANALYSIS, RNA; TRANSCRIPTOME; UTERINE NEOPLASMS;

EID: 84956834927     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.20     Document Type: Article

References (41)

1. Guillemette C, Levesque E, Harvey M, Bellemare J, Menard V. UGT genomic diversity: beyond gene duplication. Drug Metab Rev 2010; 42: 24-44.
2. Guillemette C, Levesque E, Rouleau M. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin Pharmacol Ther 2014; 96: 324-339.
3. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005; 15: 677-685.
4. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999; 31: 817-899.
5. Liu W, Ramirez J, Gamazon ER, Mirkov S, Chen P, Wu K et al. Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. Hum Mol Genet 2014; 23: 5558-5569.
6. Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmoller J. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacol Ther 2014; 141: 92-116.
7. Barbarino JM, Haidar CE, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for UGT1A1. Pharmacogenet Genomics 2014; 24: 177-183.
8. Levesque E, Girard H, Journault K, Lepine J, Guillemette C. Regulation of the UGT1A1 bilirubin-conjugating pathway: role of a new splicing event at the UGT1A locus. Hepatology 2007; 45: 128-138.
9. Levesque E, Menard V, Laverdiere I, Bellemare J, Barbier O, Girard H et al. Extensive splicing of transcripts encoding the bile acid-conjugating enzyme UGT2B4 modulates glucuronidation. Pharmacogenet Genomics 2010; 20: 195-210.
10. Menard V, Eap O, Roberge J, Harvey M, Levesque E, Guillemette C. Transcriptional diversity at the UGT2B7 locus is dictated by extensive pre-mRNA splicing mechanisms that give rise to multiple mRNA splice variants. Pharmacogenet Genomics 2011; 21: 631-641.
11. Rouleau M, Roberge J, Bellemare J, Guillemette C. Dual roles for splice variants of the glucuronidation pathway as regulators of cellular metabolism. Mol Pharmacol 2014; 85: 29-36.
12. Bellemare J, Rouleau M, Harvey M, Popa I, Pelletier G, Tetu B et al. Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans. J Pathol 2011; 223: 425-435.
13. Menard V, Levesque E, Chen S, Eap O, Joy MS, Ekstrom L et al. Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer. Pharmacogenet Genomics 2013; 23: 684-696.
14. Girard H, Levesque E, Bellemare J, Journault K, Caillier B, Guillemette C. Genetic diversity at the UGT1 locus is amplified by a novel 3′ alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenet Genomics 2007; 17: 1077-1089.
15. Menard V, Collin P, Margaillan G, Guillemette C. Modulation of the UGT2B7 enzyme activity by C-terminally truncated proteins derived from alternative splicing. Drug Metab Dispos 2013; 41: 2197-2205.
16. Innocenti F, Liu W, Fackenthal D, Ramirez J, Chen P, Ye X et al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics 2008; 18: 683-697.
17. Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C et al. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem 2003; 278: 13975-13983.
18. Bushey RT, Lazarus P. Identification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility. J Pharmacol Exp Ther 2012; 343: 712-724.
19. Drogemoller BI, Wright GE, Niehaus DJ, Emsley R, Warnich L. Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment. Pharmacogenet Genomics 2013; 23: 666-674.
20. Gamazon ER, Perera M. Genome-wide approaches in pharmacogenomics: heritability estimation and pharmacoethnicity as primary challenges. Pharmacogenomics 2012; 13: 1101-1104.
21. Lepine J, Audet-Walsh E, Gregoire J, Tetu B, Plante M, Menard V et al. Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab 2010; 95: 2689-2698.
22. Levesque E, Laverdiere I, Lacombe L, Caron P, Rouleau M, Turcotte V et al. Importance of 5alpha-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer. Clin Cancer Res 2014; 20: 576-584.
23. Mercer TR, Gerhardt DJ, Dinger ME, Crawford J, Trapnell C, Jeddeloh JA et al. Targeted RNA sequencing reveals the deep complexity of the human transcriptome. Nat Biotechnol 2012; 30: 99-104.
24. Ohno S, Nakajin S. Quantitative analysis of UGT2B28 mRNA expression by realtime RT-PCR and application to human tissue distribution study. Drug Metab Lett 2011; 5: 202-208.
25. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013; 14: R36.
26. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013; 29: 15-21.
27. Levesque E, Turgeon D, Carrier JS, Montminy V, Beaulieu M, Belanger A. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry 2001; 40: 3869-3881.
28. Bushey RT, Dluzen DF, Lazarus P. Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism. Drug Metab Dispos 2013; 41: 170-179.
29. Colombo M, Blok MJ, Whiley P, Santamarina M, Gutierrez-Enriquez S, Romero A et al. Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. Hum Mol Genet 2014; 23: 3666-3680.
30. Zhao S, Chang SL, Linderman JJ, Feng FY, Luker GD. A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer. Transl Oncol 2014; S1936-5233: 00021-00027.
31. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP et al. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 2001; 121: 1136-1144.
32. Bellemare J, Rouleau M, Girard H, Harvey M, Guillemette C. Alternatively spliced products of the UGT1A gene interact with the enzymatically active proteins to inhibit glucuronosyltransferase activity in vitro. Drug Metab Dispos 2010; 38: 1785-1789.
33. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK et al. Thirteen UDP-glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001; 11: 357-368.
34. Tukey RH, Strassburg CP. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 2001; 59: 405-414.
35. Court MH, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S et al. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther 2013; 345: 297-307.
36. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028-1038.
37. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 2014; 343: 1466-1470.
38. Pimentel H, Parra M, Gee S, Ghanem D, An X, Li J et al. A dynamic alternative splicing program regulates gene expression during terminal erythropoiesis. Nucleic Acids Res 2014; 42: 4031-4042.
39. Popp MW, Maquat LE. Organizing principles of mammalian nonsense-mediated mRNA decay. Annu Rev Genet 2013; 47: 139-165.
40. Sneitz N, Court MH, Zhang X, Laajanen K, Yee KK, Dalton P et al. Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3. Pharmacogenet Genomics 2009; 19: 923-934.
41. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40: 581-616.